Ovarian Cancer Survival Across the Introduction of Targeted Treatment: A Nationwide Analysis by Histotype and Stage
Background Bevacizumab was approved for targeted therapy of ovarian cancer in 2011 by the European Medicines Agency, with the subsequent introduction of PARP (poly[ADP]-ribose polymerase) inhibitors in 2014. Improvements in outcomes of cytoreductive surgery occurred in parallel in many regions. Objectives Population...